US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
US20030232010A2
(en)
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
CA1329119C
(en)
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
US5120525A
(en)
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
CA2109528A1
(en)
|
1991-05-01 |
1992-11-02 |
Gregory A. Prince |
A method for treating infectious respiratory diseases
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
EP0530537B1
(en)
|
1991-08-12 |
1997-01-08 |
Takeda Chemical Industries, Ltd. |
Condensed pyrimidine derivatives, their production and use as antitumor agents
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
US7326535B2
(en)
|
1993-09-15 |
2008-02-05 |
Ortho Diagnostic Systems Inc. |
Immunoreactive peptides from Epstein-Barr virus
|
US7060283B1
(en)
|
1992-09-15 |
2006-06-13 |
Ortho Diagnostic Systems, Inc. |
Immunoreactive peptides from Epstein-Barr virus
|
PT671946E
(pt)
|
1992-09-15 |
2000-12-29 |
Univ Georgetown |
Peptidos imunorreactivos do virus epstein-barr
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
EP0766684A4
(en)
|
1994-06-09 |
1997-07-16 |
Smithkline Beecham Corp |
ENDOTHELINE RECEPTOR ANTAGONISTS
|
US5686578A
(en)
|
1994-08-05 |
1997-11-11 |
Immunomedics, Inc. |
Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
ATE508733T1
(de)
|
1996-03-04 |
2011-05-15 |
Penn State Res Found |
Materialien und verfahren zur steigerung der zellulären internalisierung
|
WO1997039774A1
(en)
|
1996-04-23 |
1997-10-30 |
Novopharm Biotech, Inc. |
Human monoclonal antibody specific for melanoma-associated antigen and methods of use
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US7063967B2
(en)
|
1997-05-08 |
2006-06-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US7541020B2
(en)
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6355257B1
(en)
|
1997-05-08 |
2002-03-12 |
Corixa Corporation |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
US6673901B2
(en)
|
1997-06-12 |
2004-01-06 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
US6248564B1
(en)
|
1997-08-29 |
2001-06-19 |
Harvard University |
Mutant MHC class I molecules
|
US7569674B2
(en)
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US6238667B1
(en)
|
1997-09-19 |
2001-05-29 |
Heinz Kohler |
Method of affinity cross-linking biologically active immunogenic peptides to antibodies
|
US20030103984A1
(en)
|
1998-05-04 |
2003-06-05 |
Heinz Kohler |
Fusion proteins of biologically active peptides and antibodies
|
US20040185039A1
(en)
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
US20050033033A1
(en)
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US20090075339A1
(en)
|
1997-09-19 |
2009-03-19 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
EP1073667A2
(en)
|
1998-04-28 |
2001-02-07 |
Galenica Pharmaceuticals, Inc. |
Polysaccharide-antigen conjugates
|
US20090208418A1
(en)
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
AU747231B2
(en)
|
1998-06-24 |
2002-05-09 |
Alkermes, Inc. |
Large porous particles emitted from an inhaler
|
AU1631700A
(en)
|
1998-11-23 |
2000-06-13 |
Idec Pharmaceuticals Corporation |
Tumor antigen-specific antibody-gp39 chimeric protein constructs
|
JP2002532415A
(ja)
|
1998-12-16 |
2002-10-02 |
ワーナー−ランバート・カンパニー |
Mek阻害剤による関節炎の治療
|
EP2364997A3
(en)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
EP1177181B1
(en)
|
1999-05-05 |
2009-01-28 |
Aventis Pharma Limited |
Substituted bicyclic compounds
|
IL147765A0
(en)
|
1999-07-29 |
2002-08-14 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
DE10024069A1
(de)
|
2000-05-17 |
2001-12-13 |
Gluesenkamp Karl Heinz |
Konjugat auf der Basis einer heterobifunktionalen Brückenverbindung, die mit einem Immunmodulator und einer zellerkennenden Einheit substituiert ist
|
WO2001092339A1
(en)
|
2000-05-31 |
2001-12-06 |
University Of Virginia Patent Foundation |
Molecular marker for mitosis
|
CZ303815B6
(cs)
|
2000-07-19 |
2013-05-15 |
Warner-Lambert Company |
Derivát O-substituovaného esteru 4-jodfenylaminobenzhydroxamové kyseliny a farmaceutický prípravek s jeho obsahem
|
WO2006091720A2
(en)
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20050271663A1
(en)
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP2005532253A
(ja)
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
糖タンパク質組成物
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
DE60226641D1
(de)
|
2001-12-03 |
2008-06-26 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
ES2555307T3
(es)
|
2002-03-08 |
2015-12-30 |
Eisai R&D Management Co., Ltd. |
Compuestos macrocíclicos útiles como agentes farmacéuticos
|
PT1487485E
(pt)
|
2002-03-19 |
2011-03-11 |
Powderject Res Ltd |
Adjuvantes de imidazoquinolina para vacinas de adn
|
US20030185835A1
(en)
|
2002-03-19 |
2003-10-02 |
Braun Ralph P. |
Adjuvant for vaccines
|
CA2484044A1
(en)
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinolineamines as adjuvants in hiv dna vaccination
|
US20030190308A1
(en)
|
2002-03-19 |
2003-10-09 |
Braun Ralph P. |
Adjuvant
|
US8153141B2
(en)
|
2002-04-04 |
2012-04-10 |
Coley Pharmaceutical Gmbh |
Immunostimulatory G, U-containing oligoribonucleotides
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
AU2003224916B2
(en)
|
2002-04-10 |
2009-01-08 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US20090068178A1
(en)
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
KR100485155B1
(ko)
|
2002-05-22 |
2005-04-22 |
주식회사 삼양제넥스 |
효소저항전분을 포함하는 면역활성 증강용 조성물
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
ATE415413T1
(de)
|
2002-07-15 |
2008-12-15 |
Univ Princeton |
Iap-bindende verbindungen
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
CA2495570C
(en)
|
2002-08-15 |
2012-12-04 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
WO2004038002A2
(en)
|
2002-10-25 |
2004-05-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulation of dendritic cell function and other cellular responses mediated by defensin compositions
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1594533B1
(en)
|
2003-01-31 |
2012-04-11 |
Celldex Research Corporation |
Antibody vaccine conjugates and uses therefor
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
US7375180B2
(en)
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
EP1605893A4
(en)
|
2003-03-05 |
2008-08-13 |
Innexus Biotechnology Inc |
TRANS-MEMBRANE ANTIBODY-INDUCED APOPTOSIS INHIBITION
|
WO2004091500A2
(en)
|
2003-04-10 |
2004-10-28 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
AU2004252409A1
(en)
|
2003-04-10 |
2005-01-06 |
3M Innovative Properties Company |
Methods and compositions for enhancing immune response
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2005001855A1
(ja)
|
2003-06-27 |
2005-01-06 |
Tdk Corporation |
R-t-b系永久磁石
|
CA2535338C
(en)
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
AU2004268616B2
(en)
|
2003-08-25 |
2010-10-07 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
WO2005018574A2
(en)
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
WO2005033049A2
(en)
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
|
US20050239733A1
(en)
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050175630A1
(en)
|
2003-12-23 |
2005-08-11 |
Eyal Raz |
Immunogenic compositions and methods of use thereof
|
AU2003290460A1
(en)
|
2003-12-24 |
2005-07-14 |
Leiden University Medical Center |
Synthetic protein as tumor-specific vaccine
|
JP2007522116A
(ja)
|
2004-01-16 |
2007-08-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
コンホメーションが制約されたSmac模倣物およびその使用
|
JP2007523061A
(ja)
|
2004-01-16 |
2007-08-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Smacペプチドミメティクスおよびその使用法
|
US20060002941A1
(en)
|
2004-01-23 |
2006-01-05 |
Vievax Corp. |
Compositions comprising immune response altering agents and methods of use
|
EP1713806B1
(en)
|
2004-02-14 |
2013-05-08 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
US7345081B2
(en)
|
2004-03-23 |
2008-03-18 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
AU2005231956B2
(en)
|
2004-04-07 |
2009-11-05 |
Novartis Ag |
Inhibitors of IAP
|
US20070166384A1
(en)
|
2004-04-09 |
2007-07-19 |
Zarraga Isidro Angelo E |
Methods , composition and preparations for delivery of immune response modifiers
|
WO2005107760A1
(en)
|
2004-04-30 |
2005-11-17 |
Irm Llc |
Compounds and compositions as inducers of keratinocyte differentiation
|
RU2389731C2
(ru)
|
2004-06-02 |
2010-05-20 |
Такеда Фармасьютикал Компани Лимитед |
Конденсированное гетероциклическое соединение
|
WO2006080946A2
(en)
|
2004-06-08 |
2006-08-03 |
Coley Pharmaceutical Gmbh |
Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
|
RS53734B1
(en)
|
2004-07-02 |
2015-06-30 |
Genentech Inc. |
IAP INHIBITORS
|
US7674787B2
(en)
|
2004-07-09 |
2010-03-09 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
MX2007000490A
(es)
|
2004-07-12 |
2007-06-11 |
Idun Pharmaceuticals Inc |
Analogos de tetrapeptido.
|
WO2006020060A2
(en)
|
2004-07-15 |
2006-02-23 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
US20070129320A9
(en)
|
2004-07-18 |
2007-06-07 |
Coley Pharmaceutical Group, Ltd. |
Methods and compositions for inducing innate immune responses
|
JP2008507520A
(ja)
|
2004-07-22 |
2008-03-13 |
ジェネンテック・インコーポレーテッド |
Her2抗体組成物
|
US20060045885A1
(en)
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
Method of eliciting an immune response against HIV
|
RU2412947C2
(ru)
|
2004-09-23 |
2011-02-27 |
Дженентек, Инк. |
Антитела, сконструированные на основе цистеинов, и их конъюгаты
|
SI1797127T1
(sl)
|
2004-09-24 |
2017-09-29 |
Amgen Inc. |
Modificirane fc-molekule
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20060135459A1
(en)
|
2004-11-09 |
2006-06-22 |
Epstein Alan L |
Targeted innate immunity
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
WO2006101783A2
(en)
|
2005-03-15 |
2006-09-28 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
US7976852B2
(en)
|
2005-04-26 |
2011-07-12 |
Eisai R&D Management Co., Ltd. |
Compositions and methods for cancer immunotherapy
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
DK1907424T3
(en)
|
2005-07-01 |
2015-11-09 |
Squibb & Sons Llc |
HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
|
AU2006272837B2
(en)
|
2005-07-21 |
2012-08-23 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of MEK
|
WO2008020827A2
(en)
|
2005-08-01 |
2008-02-21 |
Biogen Idec Ma Inc. |
Altered polypeptides, immunoconjugates thereof, and methods related thereto
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1962909A4
(en)
|
2005-12-20 |
2012-04-18 |
Idera Pharmaceuticals Inc |
IMMUNOSTIMULATING ACTIVITY OF PALINDROMIC IMMUNOMODULATORY OLIGONUCLEOTIDES (IMO TM) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
PT2502938E
(pt)
|
2006-10-27 |
2015-06-05 |
Genentech Inc |
Anticorpos e imunoconjugados e suas utilizações
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
CA2683392A1
(en)
|
2007-04-30 |
2008-11-06 |
Genentech, Inc. |
Inhibitors of iap
|
ES2437327T3
(es)
|
2007-06-18 |
2014-01-10 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor PD-1 humano de muerte programada
|
WO2009002939A2
(en)
|
2007-06-23 |
2008-12-31 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
MX338504B
(es)
|
2007-09-12 |
2016-04-20 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
|
CA2698541C
(en)
|
2007-10-19 |
2018-01-09 |
Genentech, Inc. |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
AU2008328785A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
CA2713137C
(en)
|
2008-01-25 |
2017-10-24 |
Hadasit Medical Research Services And Development Ltd. |
Targeting of innate immune response to tumor site
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
UY31631A1
(es)
|
2008-02-06 |
2009-09-30 |
|
Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
|
US8747847B2
(en)
|
2008-02-11 |
2014-06-10 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
CN102046195A
(zh)
|
2008-04-02 |
2011-05-04 |
宏观基因有限公司 |
HER2/neu-特异性抗体和其使用方法
|
EP2383292A1
(en)
*
|
2008-05-02 |
2011-11-02 |
Novartis AG |
Improved fibronectin-based binding molecules and uses thereof
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
US20110223188A1
(en)
|
2008-08-25 |
2011-09-15 |
Solomon Langermann |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
PE20110435A1
(es)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
Composiciones antagonistas del pd-1
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
BRPI0917592B1
(pt)
|
2008-12-09 |
2021-08-17 |
Genentech, Inc |
Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
CN102802661B
(zh)
|
2009-06-22 |
2016-01-13 |
米迪缪尼有限公司 |
用于位点特异性偶联的工程改造的Fc区
|
JP2012532838A
(ja)
|
2009-07-09 |
2012-12-20 |
エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
安定化された免疫グロブリン定常ドメイン
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
PL2330131T3
(pl)
|
2009-12-07 |
2015-05-29 |
Fundacio Privada Inst Catalana De Recerca I Estudis Avancants |
Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
EP2558501B1
(en)
|
2010-04-15 |
2016-09-07 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
WO2011140338A1
(en)
|
2010-05-05 |
2011-11-10 |
Gatekeeper Pharmaceuticals, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
JP2013166700A
(ja)
|
2010-06-02 |
2013-08-29 |
Dainippon Sumitomo Pharma Co Ltd |
新規4,5−縮環ピリミジン誘導体
|
SG185428A1
(en)
|
2010-06-08 |
2012-12-28 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
AU2011269989B2
(en)
|
2010-06-23 |
2014-12-11 |
Hanmi Science Co., Ltd. |
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
KR20130108295A
(ko)
|
2010-08-13 |
2013-10-02 |
베일러 리서치 인스티튜트 |
항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
|
US20120328605A1
(en)
|
2010-10-27 |
2012-12-27 |
Daniel Larocque |
Compositions and uses
|
US20120231023A1
(en)
*
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2570125A1
(en)
|
2011-09-16 |
2013-03-20 |
Almirall, S.A. |
Ep1 receptor ligands
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013179174A1
(en)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Lighting arrangement
|
US20150104468A1
(en)
|
2012-06-04 |
2015-04-16 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
PL2906563T3
(pl)
*
|
2012-10-10 |
2018-10-31 |
Janssen Sciences Ireland Uc |
Pochodne pirolo[3,2-d]pirymidyny do leczenia infekcji wirusowych i innych chorób
|
CA2888445A1
(en)
*
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Methods for making conjugates from disulfide-containing proteins
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
KR102447350B1
(ko)
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
UY35397A
(es)
|
2013-03-12 |
2014-10-31 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
|
US9789203B2
(en)
*
|
2013-03-15 |
2017-10-17 |
Novartis Ag |
cKIT antibody drug conjugates
|
EP2968591A1
(en)
|
2013-03-15 |
2016-01-20 |
Novartis AG |
Cell proliferation inhibitors and conjugates thereof
|
JP6453855B2
(ja)
|
2013-05-18 |
2019-01-16 |
アドゥロ バイオテック,インク. |
「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
|
SI3030563T1
(sl)
|
2013-06-27 |
2017-12-29 |
Janssen Sciences Ireland Uc |
Derivati pirolo (3,2-d) pirimidina za zdravljenje virusnih okužb in drugih bolezni
|
ES2729643T3
(es)
|
2013-11-26 |
2019-11-05 |
Novartis Ag |
Métodos para la conjugación de oxima con polipéptidos modificados con cetona
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
US20160340439A1
(en)
*
|
2014-01-22 |
2016-11-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy
|
EA201691827A1
(ru)
*
|
2014-03-12 |
2017-01-30 |
Новартис Аг |
Конкретные участки для модификации антител с целью получения иммуноконъюгатов
|
JP6726658B2
(ja)
|
2014-04-11 |
2020-07-22 |
イェン、ユンYEN,Yun |
ヒストン脱アセチル化酵素阻害剤
|
US9944649B2
(en)
*
|
2014-05-01 |
2018-04-17 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
AU2015253215B2
(en)
|
2014-05-01 |
2017-04-13 |
Novartis Ag |
Compounds and compositions as Toll-Like Receptor 7 agonists
|
MX2016016515A
(es)
|
2014-06-13 |
2017-04-27 |
Novartis Ag |
Derivados de auristatina y conjugados de los mismos.
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
TWI727427B
(zh)
|
2014-07-09 |
2021-05-11 |
英屬開曼群島商博笛生物科技有限公司 |
用於治療腫瘤的抗pd-1組合
|
WO2016011422A2
(en)
|
2014-07-17 |
2016-01-21 |
Czerniecki Brian J |
Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
|
JP6967963B2
(ja)
|
2014-07-17 |
2021-11-17 |
ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. |
複数用量注射準備済樹状細胞ワクチンの製造ならびにher2およびher3を遮断するための併用療法
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
CN106794246B
(zh)
|
2014-08-08 |
2021-10-15 |
OncoQuest制药有限公司 |
肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
|
CN112898308A
(zh)
|
2014-08-15 |
2021-06-04 |
正大天晴药业集团股份有限公司 |
作为tlr7激动剂的吡咯并嘧啶化合物
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
EP3215519A1
(en)
|
2014-11-06 |
2017-09-13 |
Novartis AG |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
CN104650228B
(zh)
|
2014-11-26 |
2017-11-28 |
嘉和生物药业有限公司 |
一种全人源her2抗体、其编码基因及应用
|
HUE053704T2
(hu)
|
2014-12-08 |
2021-07-28 |
Hoffmann La Roche |
3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
|
US10668165B2
(en)
|
2015-01-16 |
2020-06-02 |
Immunwork Inc. |
Molecular constructs for treating tumors
|
CN107847588B
(zh)
|
2015-05-20 |
2021-12-28 |
免疫功坊股份有限公司 |
具有靶向部分及效应部分的分子构建体及其应用
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN115300640A
(zh)
|
2015-08-10 |
2022-11-08 |
杭州多禧生物科技有限公司 |
新型连接体及其用于药物和生物分子的特异性偶联
|
MX2018002319A
(es)
|
2015-08-24 |
2018-04-11 |
Glaxosmithkline Ip No 2 Ltd |
Composiciones biofarmaceuticas.
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
BR112018008880B1
(pt)
|
2015-11-05 |
2023-01-17 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
7-(tiazol-5-il) pirrolopirimidina, seu uso, e composição farmacêutica
|
EP3411074A4
(en)
|
2016-02-04 |
2019-09-04 |
Suzhou M-conj Biotech Co., Ltd. |
SPECIFIC, IMMUNOCONJUGUATED CONJUGATION LINKS SPECIFIC THEREOF, METHODS OF MAKING AND USES OF SAID CONJUGATES THEREOF
|
CN107043379A
(zh)
|
2016-02-05 |
2017-08-15 |
正大天晴药业集团股份有限公司 |
一种tlr7激动剂的晶型a、其制备方法和医药用途
|